The net profit of Guangji Pharmaceutical will increase by 47.5% in 2021 as it strives to implement the strategy of “API + Preparation + big health”

2022-06-12 0 By

Guangji Pharmaceutical co., LTD. (000952.SZ) recently released the annual performance report said that 2021 operating revenue of 837 million yuan, a year-on-year increase of 21.64%;Net profit attributable to shareholders of listed companies was 110 million yuan, an increase of 47.5%;Basic earnings per share profit of 0.3201 yuan, up 43.41% year on year.The distribution plan is to distribute 0.6 yuan of cash bonus (including tax) for every 10 shares, no bonus shares and no additional shares.Guangji pharmaceutical mainly produces vitamin B2, B6 and pharmaceutical preparation products, which are mainly used as pharmaceutical raw materials, food additives and dietary supplements, feed additives, and is the world’s major supplier of vitamin B2 products.In the face of the pharmaceutical industry market changes and competition pressure, wide pharmaceutical said, the company closely around the core areas of biological fermentation technology, implementation of the “active pharmaceutical ingredients, preparation and health” in depth strategy, build “gathered biological fermentation technology innovation elements” of the industrialization of the platform, will be widely dhi pharmaceutical industry to develop into has the world influence, the domestic benchmarking biological fermentation technology of leading enterprises.Data show that in the main business of Guangji Pharmaceutical company in 2021, the revenue of raw material series products is 571 million yuan, accounting for 68.17% of the operating revenue, with a year-on-year growth of 5.69%;Other products revenue of 155 million yuan, accounting for 18.48% of the operating revenue, a year-on-year growth of 307.59%;The revenue of pharmaceutical products was 111 million yuan, accounting for 13.29% of the operating revenue, with a year-on-year growth of 2.04%.During the reporting period, Guangji pharmaceutical actively expand new products.To build product clusters featuring B vitamins, strengthen the core competitiveness of VB2 products, accelerate the registration of “1831” in the European Union, and realize the sales of high-quality VB2 as soon as possible.Accelerate the development of VB6 industrial chain and accelerate the industrial production of pyridoxal phosphate.Accelerate the construction of comprehensive utilization project of VB12 (1%) with an annual output of 1000 tons, enrich the company’s vitamin product categories, and promote the development of VB12 for food and medicine.Moxifloxacin hydrochloride and other products will be accelerated in the consistency evaluation of pharmaceutical preparations.At the same time, independent research and development of health products multivitamin tablets, cooperation in the development of high value-added dietary supplement products.During the reporting period, the total sales amount of the company’s top five customers was 271 million yuan, accounting for 32.32% of the total sales amount, and the total purchase amount of the company’s top five suppliers was 144 million yuan, accounting for 32.22% of the total annual purchase amount.In terms of sales channels, broadly dhi pharmaceutical industry and its holdings of hubei co., LTD., in-depth cooperation, make full use of the partner’s hospital courtyard line, terminal distribution, retail chain, API business, supply chain services, sales of third-party logistics and other advantages, broaden the medicine marketing channels, medical and pharmaceutical preparation sales year-on-year increase more than 50%.The sales volume of 98%VB2 and riboflavin sodium phosphate in the Domestic trade department reached the highest in history.Ministry of Foreign Trade sales of high-content VB2 increased 10.9% year on year.Guangji Pharmaceutical said that in 2022, it will continue to carry out comprehensive cooperation with Sinoprevention Hubei Co., LTD., to make up the short board of production and sales of pharmaceutical preparations of Guangji Pharmaceutical and expand marketing channels.At present, Guangji Pharmaceutical is accelerating the construction of medical technology laboratory to enhance its independent research and development capacity, which is expected to be completed and put into use by the end of the year.In 2021, guangji Pharmaceutical r&d layout of a number of products are stepping up research and development.During the reporting period, Guangji Pharmaceutical incorporated the introduction of research and development team, jointly funded with the research and development team to accelerate the construction of biotechnology research institute, and increase the transformation of research and development results.Set up industrial innovation alliance, cooperate deeply with experts from huakuke, Wuwu university and other research institutes, integrate R&D resources and improve r&d efficiency.In 2021, it has completed 3 patent applications, 5 consistency evaluation products and 11 new product development projects.In terms of core products, the company introduced expert technology innovation to reduce costs, and successfully conducted tests on vitamin B at 600g and kg levels.VB2 process technology is improved, and the output of finished products in single tank is a record high.Riboflavin sodium phosphate process upgrade, effectively solve the production of recycled materials, improve product quality.Guangji Pharmaceutical said that in 2022, it will speed up the construction of research and development laboratories of pharmaceutical technology companies, biological fermentation technology pilot workshop and chemical synthesis pilot workshop, and build a pilot transformation platform with both “biological fermentation” and “chemical synthesis”.Through joint development, cooperation and other ways, accelerate the development of vitamin B series, pharmaceutical preparations and health care products, enrich product lines, and form the product echelon of “API + preparation + big health”.Guangji Pharmaceutical is a state-owned high-tech enterprise with more than 50 years of experience. It is a key high-tech enterprise identified by the Ministry of Science and Technology as “Torch Plan” and awarded as “International Science and Technology Cooperation Base”, “High-tech Achievement Demonstration Base” identified by the National Development and Reform Commission, and has undertaken the national “863 Plan”.China Feed Industry Association has also been rated as “National feed additives science and technology Innovation excellent enterprise”, “National top 50 feed enterprises”.Hubei provincial government awarded “Top 100 Foreign trade enterprises in Hubei” title.In 2021, Guangji Pharmaceutical became the first batch of “benchmark on the cloud” enterprises in Hubei Province, and the specialized new “little giant” enterprises in Hubei Province.Disclaimer: This article is reproduced for the purpose of conveying more information.If the source is wrong or violated your legitimate rights and interests, please contact the author with proof of ownership, we will promptly correct, delete, thank you.Email address: newmedia@xxcb.cn